Pre-clinical (normoalbuminuria)
出自KMU Wiki
(修訂版本間差異)
| 在2018年3月27日 (二) 12:59所做的修訂版本 (編輯) Guhjy (對話 | 貢獻) ←上一個 |
在2018年3月27日 (二) 12:59所做的修訂版本 (編輯) (撤銷) Guhjy (對話 | 貢獻) 下一個→ |
||
| 第3行： | 第3行： | ||
| *Mesangial expansion/sclerosis (PAS+) | *Mesangial expansion/sclerosis (PAS+) | ||
| *Pathogenesis | *Pathogenesis | ||
| - | **Glomerular hypertension, hyperfiltration, proteinuria, hyperglycemia, advanced glycosylation end products, growth hormone, atrial natriuretic peptide, insulin-like growth factor I, angiotensin II (efferent arteriole constriction), connective tissues growth factor, transforming growth factor-&beta, hyperlipidemia | + | **Glomerular hypertension, hyperfiltration, proteinuria, hyperglycemia, advanced glycosylation end products, growth hormone, atrial natriuretic peptide, insulin-like growth factor I, angiotensin II (efferent arteriole constriction), connective tissues growth factor, transforming growth factor- &beta, hyperlipidemia |
在2018年3月27日 (二) 12:59所做的修訂版本
- Urinary albumin excretion< 30 mg/g creatinine
- < 5 year, renal hypertrophy, hyperfiltration, intrarenal hypertension, thick GBM (cannot predict progression), loss of heparan sulfate (negative charge)-->albuminuria
- Mesangial expansion/sclerosis (PAS+)
- Pathogenesis
- Glomerular hypertension, hyperfiltration, proteinuria, hyperglycemia, advanced glycosylation end products, growth hormone, atrial natriuretic peptide, insulin-like growth factor I, angiotensin II (efferent arteriole constriction), connective tissues growth factor, transforming growth factor- &beta, hyperlipidemia
